Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis

Table 3

Analysis of the predictive performance of each model in subgroups.

Model	Subgroup		AUC^†	95% CI^#	I^2
CU-HCC	Antiviral therapy	Receiving	0.731	0.705, 0.756	0.0%
		Not receiving	0.731	0.689, 0.768	0.0%
	Cirrhosis	Yes	0.582	0.522, 0.641	45.8%
		No	0.672	0.489, 0.815	85.1%
GAG-HCC	Antiviral therapy	Receiving	0.760	0.734, 0.783	1.1%
		Not receiving	0.773	0.681, 0.845	0.0%
	Cirrhosis	Yes	—^§	—	—
		No	—	—	—
PAGE-B	Antiviral therapy	Receiving	0.741	0.707, 0.772	28.2%
		Not receiving	—	—	—
	Cirrhosis	Yes	—	—	—
		No	—	—	—
mPAGE-B	Antiviral therapy	Receiving	0.778	0.749, 0.804	43.7%
		Not receiving	—	—	—
	Cirrhosis	Yes	—	—	—
		No	—	—	—
REACH-B	Antiviral therapy	Receiving	0.639	0.612, 0.666	0.0%
		Not receiving	0.763	0.744,0.781	37.9%
	Cirrhosis	Yes	0.648	0.613, 0.682	0.0%
		No	0.774	0.721, 0.820	79.6%
mREACH-B	Antiviral therapy	Receiving	0.785	0.750, 0.817	23.4%
		Not receiving	0.789	0.737, 0.833	0.0%
	Cirrhosis	Yes	0.688	0.653, 0.721	0.0%
		No	0.785	0.700, 0.851	65.5%

AUC: area under the receiver operator characteristic curve; CI: confidence interval. The symbol § means that the information cannot be extracted.